APA (7th ed.) Citation

L, B., G, C., JF, S., A, P., A, S., D, O., . . . P, S. (2020). A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. International journal of cancer, 146(5), 1409. https://doi.org/10.1002/ijc.32777

Chicago Style (17th ed.) Citation

L, Bellmann, et al. "A TLR7 Agonist Strengthens T and NK Cell Function During BRAF-targeted Therapy in a Preclinical Melanoma Model." International Journal of Cancer 146, no. 5 (2020): 1409. https://doi.org/10.1002/ijc.32777.

MLA (9th ed.) Citation

L, Bellmann, et al. "A TLR7 Agonist Strengthens T and NK Cell Function During BRAF-targeted Therapy in a Preclinical Melanoma Model." International Journal of Cancer, vol. 146, no. 5, 2020, p. 1409, https://doi.org/10.1002/ijc.32777.